Regeneron Pharmaceuticals (REGN) Posts Q4 Loss of 37c/Share
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $783.54 -0.75%
EPS Growth %: +35.2%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +35.2%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of ($0.37), $0.23 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $123 million versus the consensus estimate of $131.04 million.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Can global equities keep rising? UBS sees these factors driving upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
